MX2018015353A - Usos terapeuticos de un inhibidor de c-raf. - Google Patents
Usos terapeuticos de un inhibidor de c-raf.Info
- Publication number
- MX2018015353A MX2018015353A MX2018015353A MX2018015353A MX2018015353A MX 2018015353 A MX2018015353 A MX 2018015353A MX 2018015353 A MX2018015353 A MX 2018015353A MX 2018015353 A MX2018015353 A MX 2018015353A MX 2018015353 A MX2018015353 A MX 2018015353A
- Authority
- MX
- Mexico
- Prior art keywords
- raf inhibitor
- relates
- present
- combination
- harbors
- Prior art date
Links
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 title abstract 3
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 4
- 108091054455 MAP kinase family Proteins 0.000 abstract 4
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348720P | 2016-06-10 | 2016-06-10 | |
| PCT/IB2017/053405 WO2017212442A1 (en) | 2016-06-10 | 2017-06-08 | Therapeutic uses of a c-raf inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015353A true MX2018015353A (es) | 2019-09-09 |
Family
ID=59215827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015353A MX2018015353A (es) | 2016-06-10 | 2017-06-08 | Usos terapeuticos de un inhibidor de c-raf. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190175609A1 (OSRAM) |
| EP (1) | EP3468595A1 (OSRAM) |
| JP (1) | JP2019517549A (OSRAM) |
| KR (1) | KR20190017767A (OSRAM) |
| CN (1) | CN109310761A (OSRAM) |
| AU (1) | AU2017279046B2 (OSRAM) |
| BR (1) | BR112018075371A2 (OSRAM) |
| CA (1) | CA3026876A1 (OSRAM) |
| CL (1) | CL2018003530A1 (OSRAM) |
| IL (1) | IL262961A (OSRAM) |
| MX (1) | MX2018015353A (OSRAM) |
| RU (1) | RU2018146886A (OSRAM) |
| WO (1) | WO2017212442A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017329090B9 (en) * | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| JP7483741B2 (ja) | 2019-03-08 | 2024-05-15 | オーリス ヘルス インコーポレイテッド | 医療システム用の傾斜機構及び用途 |
| CA3138123A1 (en) | 2019-05-13 | 2020-11-19 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| BR112022007612A2 (pt) | 2019-10-24 | 2022-09-20 | Kinnate Biopharma Inc | Inibidores de raf quinases |
| CN114746417B (zh) * | 2019-12-06 | 2023-12-08 | 齐鲁制药有限公司 | Pan-RAF激酶抑制剂的联芳基化合物 |
| CN113912591B (zh) * | 2020-07-08 | 2023-10-20 | 齐鲁制药有限公司 | 联芳基化合物 |
| WO2022253334A1 (zh) * | 2021-06-04 | 2022-12-08 | 南京明德新药研发有限公司 | 一种raf激酶抑制剂的晶型及其制备方法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CN118286440A (zh) * | 2014-02-04 | 2024-07-05 | 辉瑞大药厂 | 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合 |
| AR101210A1 (es) * | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
-
2017
- 2017-06-08 MX MX2018015353A patent/MX2018015353A/es unknown
- 2017-06-08 CA CA3026876A patent/CA3026876A1/en not_active Abandoned
- 2017-06-08 EP EP17733028.9A patent/EP3468595A1/en not_active Withdrawn
- 2017-06-08 CN CN201780035192.1A patent/CN109310761A/zh active Pending
- 2017-06-08 US US16/307,920 patent/US20190175609A1/en not_active Abandoned
- 2017-06-08 WO PCT/IB2017/053405 patent/WO2017212442A1/en not_active Ceased
- 2017-06-08 JP JP2018564296A patent/JP2019517549A/ja active Pending
- 2017-06-08 AU AU2017279046A patent/AU2017279046B2/en not_active Ceased
- 2017-06-08 KR KR1020187035219A patent/KR20190017767A/ko not_active Ceased
- 2017-06-08 RU RU2018146886A patent/RU2018146886A/ru not_active Application Discontinuation
- 2017-06-08 BR BR112018075371-8A patent/BR112018075371A2/pt not_active Application Discontinuation
-
2018
- 2018-11-12 IL IL262961A patent/IL262961A/en unknown
- 2018-12-07 CL CL2018003530A patent/CL2018003530A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019517549A (ja) | 2019-06-24 |
| IL262961A (en) | 2018-12-31 |
| EP3468595A1 (en) | 2019-04-17 |
| CA3026876A1 (en) | 2017-12-14 |
| BR112018075371A2 (pt) | 2019-03-19 |
| CN109310761A (zh) | 2019-02-05 |
| RU2018146886A (ru) | 2020-07-10 |
| AU2017279046A1 (en) | 2018-12-06 |
| KR20190017767A (ko) | 2019-02-20 |
| US20190175609A1 (en) | 2019-06-13 |
| RU2018146886A3 (OSRAM) | 2020-10-15 |
| CL2018003530A1 (es) | 2019-02-15 |
| AU2017279046B2 (en) | 2020-07-02 |
| WO2017212442A1 (en) | 2017-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| PH12019500270A1 (en) | Combination therapy for cancer | |
| MX386413B (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| MY195474A (en) | Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1) | |
| CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| MX2018005720A (es) | Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| HK1254635A1 (zh) | C-met抑制剂与pd-1抗体分子的组合及其用途 | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| HK1247129A1 (zh) | 治疗癌症的联合疗法 | |
| MX2017001976A (es) | Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano. | |
| WO2016028391A3 (en) | Spiropyrrolidines as mdm2 inhibitors | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2015191568A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature | |
| IN2015DN00528A (OSRAM) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| WO2016100738A3 (en) | Antifibrotic activity of gas6 inhibitor | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| EP4613333A3 (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors |